The Broad View
In the global scramble to develop a COVID-19 vaccine, brand-name biopharmaceutical giants in the United States and Europe appear to have promising candidates. But there are also several lesser known companies playing a role in helping produce a potential vaccine.
Three of 10-plus vaccines in advanced clinical trials globally are being developed by Chinese firms, which is quite remarkable given where the country had been. Party leaders just a decade ago embarked on structural reforms to modernize the country’s health care system, root out corruption, boost drug quality and create infrastructure to nurture the development of homegrown biopharmaceutical firms.
After living in Hong Kong and spending the past decade visiting and researching health care companies in China, it’s been fascinating to see development move at such a rapid pace. And we are only in the early innings of this potentially massive transformation. Looking back at the evolution of the U.S. biotech industry, China by comparison is moving at three times the speed. Everything in China is bigger and faster, powered by top-down economic policies.
Over the next decade, China’s strategic policy initiatives in biomedicine could have broad ramifications for investments in the global pharmaceutical sector and in China itself. Based on our current growth projections, China is steadily closing the gap between it and the U.S. market. This growth comes as China is already the largest global supplier of active pharmaceutical ingredients, a point that has raised concerns during the pandemic given rising geopolitical tensions and policies promoting domestic protectionism.
At the same time, China is beginning to export new and innovative drugs, too. BeiGene last year was the first company to secure U.S. regulatory approvals for a drug largely based on clinical data generated in China. So even in this tense geopolitical climate, I believe prospects remain encouraging for both multinationals and local Chinese firms as China makes a strong push to move up the value chain in health care. U.K.-based AstraZeneca might be one of those beneficiaries: It currently counts 20% of its global revenue from China through partnerships it’s cultivated with four local firms.
Aging demographics: China looks more like its western counterparts than the young and vibrant populations typically associated with emerging market countries. The median age in China, which was just 19 in 1970, reached 38 this year and will be 47 by 2040, according to United Nations projections. With this greying population has come a rise in medical ailments, including diabetes and cancer, which has forced the government into action.
Consumer demand: Consumer awareness and demand for better health care has risen dramatically in China, especially with a rising middle class that is willingly to pay for out-of-pocket medical expenses. Vaccine quality is discussed extensively in social media, and vaccines made by multinationals that are available in China are often out of stock because demand exceeds supply.
Government reforms: Plagued with scandals of low quality and ineffective products considered obsolete elsewhere, questionable operators and poor supply chains, both the government and the public have pushed for the sector to be cleaned up. The policy response has been to significantly raise the bar on generic drug quality, encourage local companies to innovate premium drugs and expand access to better medicines. This has included making changes to stimulate a vibrant ecosystem of early stage innovative biopharma companies. Meteoric rises in valuation and global visibility of some of the leaders like WuXi AppTec has inspired many others.
Government health insurance programs also began reimbursing newer, more expensive and better quality drugs (produced both by multinationals and local companies) for the first time.
We’ve also noticed that China’s regulators have expressed less interest in indirect protectionism of domestic companies; it now sees its role as providing the public with safer and more efficacious medicines regardless of who makes them.
Another emphasis has been making the drug review process more efficient. The number of reviewers for China’s Center for Drug Evaluation grew to several thousand from just 120 reviewers in 2015. By comparison, in the same capacity the U.S. Food and Drug Administration employs approximately 6,000 and Japan’s equivalent agency has around a 1,000.
This has helped the government make changes to “triage” drug applications to separate and accelerate those that are innovative and addressing substantial unmet medical needs from those that are redundant and undifferentiated (e.g., the 20th or 50th generic entrant).
Spending growth: China is one of the few large economies in the world that is markedly increasing health care expenditures. While it is still low on a relative basis, I expect spending to increase. For instance, in 2018 (latest figures available) health spending accounted for only 6.6% of the country’s gross domestic product; it is expected to be above 7% this year. In comparison, the U.S. spends 18% of its GDP on health care and Germany, 11%.
There are advantages for multinationals to partner with local companies in China. These include:
Given these considerations, I expect collaborative efforts even as politicians in the U.S. and Europe weigh the merits of reconstructing parts of their global supply chains. The upside: If it’s possible to speed up global clinical trials by doing parts of them cheaper in China without compromising quality, it could speed time to market by a year or two and reduce total development costs. For instance, California-based Amgen and BeiGene, which operates dual headquarters in Beijing and Massachusetts, have teamed up to develop 20 cancer drugs in Amgen’s pipeline.
BeiGene is a further illustration of a new breed of biotech firm emerging in China: It has a deep bench of senior talent with decades of experience working for multinationals and focuses on both China and the U.S.
Talent is key to pushing toward the next level of innovation, and the tide of human capital is shifting — an historic brain drain of scientists leaving China for the U.S. and Europe is becoming a brain gain. Many in the field have returned to China; others never left, given the growing number of promising opportunities. We are finding that deep-pocketed startups are poaching top talent from multinationals and compensation packages have risen dramatically for some key roles.
Venture capital funding has surged for health care startups in China, with roughly $60 billion invested since 2015, according to data from ChinaBio Consulting. Amid this optimism, there’s been a wave of investment bankers and sell-side analysts from Wall Street banks joining startups as CFOs, as well as top scientists from multinational biopharma companies making similar moves to well-funded startups.
In capital markets, China’s push to transform its health care industry is changing the complexion of the benchmark MSCI China Investable Market Index. Back in 2010, health care was the smallest sector by weight in the index — and as of June 30 it ranked as the fourth largest at 5.7% as company market values have climbed dramatically. The government also launched the Shanghai Exchange Science and Technology Innovation Board (STAR Board), where a number of early-stage biotech companies have debuted since listings began a year ago.
In my view, what is underappreciated today is that China is starting to contribute from an innovation perspective globally. There are some early-stage companies working on potential drugs that could become first-rate medicines on a global basis. I am seeing this in the cell therapy space, where China has just as many trials in progress as the U.S., and in some areas of cancer research, where China’s pipeline is almost as rich as the U.S.
None of this will come without challenges and risks. Some drugs may never get out of trials and not all business models will succeed as competition escalates. While China’s reform achievements to date have exceeded the expectations of many, more work needs to be done to improve business practices and industry standards and there will be plenty of growing pains along the way. That said, China’s biopharma industry is moving closer to an inflection point, and the number of investment opportunities is likely to grow in the years ahead.
Investing outside the United States involves risks, such as currency fluctuations, periods of illiquidity and price volatility. These risks may be heightened in connection with investments in developing countries. Small-company stocks entail additional risks, and they can fluctuate in price more than larger company stocks.
The MSCI China Investable Market Index (IMI) captures large, mid- and small-cap representation of approximately 99% of the investable equity universe for China's mainland market. The index is unmanaged and, therefore, has no expenses. Investors cannot invest directly in an index.
MSCI has not approved, reviewed or produced this report, makes no express or implied warranties or representations and is not liable whatsoever for any data in the report. You may not redistribute the MSCI data or use it as a basis for other indices or investment products.